5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectal cancer
Bliss E, Robert G
Record ID 31998008877
English
Authors' objectives:
The authors examine how worthwhile is the proposal that all patients with Duke's stage C colorectal cancer be offered 5-fluorouracil (5-FU) as adjuvant chemotherapy following surgery.
Authors' results and conclusions:
100 patients given 5-FU/FA would be expected to gain 24 life years compared with respective patients randomised to receive surgery alone. The results for 5-FU/levamisole were similar (23 life years gained).
Authors' recommendations:
There are undoubted benefits, but in view of side effects the cost of QALYs is likely to be at the upper end of the range.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.wihrd.soton.ac.uk
Year Published:
1996
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England
MeSH Terms
- Chemotherapy, Adjuvant
- Costs and Cost Analysis
- Colorectal Neoplasms
Contact
Organisation Name:
Wessex Institute for Health Research and Development
Contact Address:
Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Copyright:
Wessex Institute for Health Research and Development (WIHRD)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.